{"disease":{"id":"ocular-graft-versus-host-disease","name":"ocular graft versus host disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06348602","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Hospital Universitario Dr. Jose E. Gonzalez","has_results":false},{"nct_id":"NCT04769648","title":"Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Glia, LLC","has_results":false},{"nct_id":"NCT05311514","title":"Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT03990051","title":"Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Glia, LLC","has_results":true},{"nct_id":"NCT04792580","title":"The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Richard W Yee, MD","has_results":false},{"nct_id":"NCT03298815","title":"Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT07166848","title":"Electrostimulation Study for Ocular Graft vs. Host Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Zhonghui K. Luo, MD, PhD","has_results":false},{"nct_id":"NCT06952114","title":"A Study of Stem Cells Lenses in the coGVHD Subjects","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Guangdong ProCapZoom Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT06495307","title":"RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Lubris Bio Pty Ltd","has_results":false},{"nct_id":"NCT07066865","title":"Evaluation of the Safety and Effectiveness of omniLenz in Patient With Ocular Graft vs Host Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Farwaniya Hospital","has_results":false},{"nct_id":"NCT04204122","title":"Vigamox Treatment for Ocular Graft-Versus-Host Disease","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Washington University School of Medicine","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}